FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Denis Guilloteau

Research Profile

Living Beings

Anatomy

Chemicals & Drugs

Procedures

Co-author Network

Publications

TOP 3
Emilie Beaufils; Florence Brault; Jean Philippe Cottier; Diane Dufour-Rainfray; Caroline Hommet; Karl Mondon; Maria Joao Ribeiro; Denis Guilloteau
Confirmation of the amyloidogenic process in posterior cortical atrophy: value of the Aβ42/Aβ40 ratio.
Renaud La Joie; Brigitte Landeau; Florence Mézenge; Audrey Perrotin; Ahmed Abbas; Louisa Barré; Vincent Camus; Vincent de La Sayette; Béatrice Desgranges; Francis Eustache; Denis Guilloteau; Caroline Hommet; Méziane Ibazizene; Gaël Chételat
Region-specific hierarchy between atrophy, hypometabolism, and β-amyloid (Aβ) load in Alzheimer's disease dementia.
Géraldine Poisnel; Ahmed Abbas; Jérôme Delamare; Martine Dhilly; Denis Guilloteau; Olivier Moustié; Louisa Barré
PET imaging with [18F]AV-45 in an APP/PS1-21 murine model of amyloid plaque deposition.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Denis Guilloteau (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Emilie Beaufils; Florence Brault; Jean Philippe Cottier; Diane Dufour-Rainfray; Caroline Hommet; Karl Mondon; Maria Joao Ribeiro; Denis Guilloteau
Confirmation of the amyloidogenic process in posterior cortical atrophy: value of the Aβ42/Aβ40 ratio.
Journal of Alzheimer's disease : JAD 2013;33(3):775-80.
2012: Renaud La Joie; Brigitte Landeau; Florence Mézenge; Audrey Perrotin; Ahmed Abbas; Louisa Barré; Vincent Camus; Vincent de La Sayette; Béatrice Desgranges; Francis Eustache; Denis Guilloteau; Caroline Hommet; Méziane Ibazizene; Gaël Chételat
Region-specific hierarchy between atrophy, hypometabolism, and β-amyloid (Aβ) load in Alzheimer's disease dementia.
The Journal of neuroscience : the official journal of the Society for Neuroscience 2012;32(46):16265-73.
2012: Géraldine Poisnel; Ahmed Abbas; Jérôme Delamare; Martine Dhilly; Denis Guilloteau; Olivier Moustié; Louisa Barré
PET imaging with [18F]AV-45 in an APP/PS1-21 murine model of amyloid plaque deposition.
Neurobiology of aging 2012;33(11):2561-71.
2012: Serge Maia; Jackie Vergote; Emilie Vierron; Nicolas Arlicot; Sylvie Bodard; Denis Guilloteau; Sylvie Chalon
Longitudinal and parallel monitoring of neuroinflammation and neurodegeneration in a 6-hydroxydopamine rat model of Parkinson's disease.
Synapse (New York, N.Y.) 2012;66(7):573-83.
2012: Nicolas Arlicot; Jean-Louis Baulieu; Philippe Corcia; Michael Kassiou; Serge Maia; Aaron Reynolds; Maria-João Ribeiro; Michael G Stabin; Clovis Tauber; Yann Venel; Johnny Vercouillie; Denis Guilloteau
Initial evaluation in healthy humans of [18F]DPA-714, a potential PET biomarker for neuroinflammation.
Nuclear medicine and biology 2012;39(4):570-8.
2012: Katherine R Leaver; Aaron Reynolds; Sylvie Bodard; Sylvie Chalon; Denis Guilloteau; Michael Kassiou
Effects of translocator protein (18 kDa) ligands on microglial activation and neuronal death in the quinolinic-acid-injected rat striatum.
ACS chemical neuroscience 2012;3(2):114-9.
2012: Sylvie Mavel; Nathalie Méheux; Zoya Mincheva; Mohamed Abarbri; Yvan Carcenac; Denis Guilloteau; Patrick Emond
QSAR study and synthesis of new phenyltropanes as ligands of the dopamine transporter (DAT).
Bioorganic & medicinal chemistry 2012;20(4):1388-95.
2012: Philippe Corcia; Jean Philippe Cottier; Denis Guilloteau; Caroline Hommet; Mickael Kassiou; Guillaume Nicolas; Julien Praline; Caroline Prunier; Catherine Roussel; Clovis Tauber; Yann Venel; Johnnie Vercoullie; Nicolas Arlicot; Jean-Louis Baulieu; Maria-Joao Ribeiro
Molecular imaging of microglial activation in amyotrophic lateral sclerosis.
PloS one 2012;7(12):e52941.
2011: Andrea Varrone; Johnny Vercouillie; Jean Bernard Deloye; Patrick Emond; Denis Guilloteau; Balázs Gulyás; Cathrine Jonsson; Ryuji Nakao; Michael G Stabin; Vladimir Stepanov; Miklós Tóth; Christer Halldin
Imaging of the striatal and extrastriatal dopamine transporter with (18)F-LBT-999: quantification, biodistribution, and radiation dosimetry in nonhuman primates.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2011;52(8):1313-21.
2011: Diane Dufour-Rainfray; Patrick Vourc'h; Sébastien Tourlet; Denis Guilloteau; Sylvie Chalon; Christian R Andres
Fetal exposure to teratogens: evidence of genes involved in autism.
Neuroscience and biobehavioral reviews 2011;35(5):1254-65.
2011: Andrea Varrone; Miklós Tóth; Carsten Steiger; Akihiro Takano; Denis Guilloteau; Masanori Ichise; Balázs Gulyás; Christer Halldin
Kinetic analysis and quantification of the dopamine transporter in the nonhuman primate brain with 11C-PE2I and 18F-FE-PE2I.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2011;52(1):132-9.
2010: Nicolas Arlicot; Edwige Petit; Andrew Katsifis; Jérôme Toutain; Didier Divoux; Sylvie Bodard; Simon Roussel; Denis Guilloteau; Myriam Bernaudin; Sylvie Chalon
Detection and quantification of remote microglial activation in rodent models of focal ischaemia using the TSPO radioligand CLINDE.
European journal of nuclear medicine and molecular imaging 2010;37(12):2371-80.
2010: Mitja Kovac; Sylvie Mavel; Winnie Deuther-Conrad; Nathalie Méheux; Jana Glöckner; Barbara Wenzel; Marko Anderluh; Peter Brust; Denis Guilloteau; Patrick Emond
3D QSAR study, synthesis, and in vitro evaluation of (+)-5-FBVM as potential PET radioligand for the vesicular acetylcholine transporter (VAChT).
Bioorganic & medicinal chemistry 2010;18(21):7659-67.
2010: Nicolas Giboureau; Ian Mat Som; Aurélie Boucher-Arnold; Denis Guilloteau; Michael Kassiou
PET radioligands for the vesicular acetylcholine transporter (VAChT).
Current topics in medicinal chemistry 2010;10(15):1569-83.
2010: Sylvie Mavel; Nathalie Meheux; Denis Guilloteau; Patrick Emond
Synthesis and in vitro evaluation of fluorinated diphenyloxide derivatives and sulfur analogs as serotonin transporter ligands.
Bioorganic & medicinal chemistry 2010;18(1):236-41.
2009: Andrea Varrone; Carsten Steiger; Magnus Schou; Akihiro Takano; Sjoerd J Finnema; Denis Guilloteau; Balázs Gulyás; Christer Halldin
In vitro autoradiography and in vivo evaluation in cynomolgus monkey of [18F]FE-PE2I, a new dopamine transporter PET radioligand.
Synapse (New York, N.Y.) 2009;63(10):871-80.
2009: Magnus Schou; Carsten Steiger; Andrea Varrone; Denis Guilloteau; Christer Halldin
Synthesis, radiolabeling and preliminary in vivo evaluation of [18F]FE-PE2I, a new probe for the dopamine transporter.
Bioorganic & medicinal chemistry letters 2009;19(16):4843-5.
2008: Sylvie Mavel; Johnny Vercouillie; Lucette Garreau; Tiziana Raguza; Aina Westrheim Ravna; Sylvie Chalon; Denis Guilloteau; Patrick Emond
Docking study, synthesis, and in vitro evaluation of fluoro-MADAM derivatives as SERT ligands for PET imaging.
Bioorganic & medicinal chemistry 2008;16(19):9050-5.
2008: Gaëlle Bouchez; Luc Sensebé; Patrick Vourc'h; Lucette Garreau; Sylvie Bodard; Angélique Rico; Denis Guilloteau; Pierre Charbord; Jean-Claude Besnard; Sylvie Chalon
Partial recovery of dopaminergic pathway after graft of adult mesenchymal stem cells in a rat model of Parkinson's disease.
Neurochemistry international 2008;52(7):1332-42.
2008: Michelle L James; Roger R Fulton; Johnny Vercoullie; David J Henderson; Lucette Garreau; Sylvie Chalon; Frederic Dolle; Barbara Costa; Silvia Selleri; Denis Guilloteau; Michael Kassiou
DPA-714, a new translocator protein-specific ligand: synthesis, radiofluorination, and pharmacologic characterization.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2008;49(5):814-22.
2008: J Mazère; Caroline Prunier; O Barret; Martine Guyot; Caroline Hommet; Denis Guilloteau; Jean-François Dartigues; Sophie Auriacombe; Colette Fabrigoule; Michele Allard
In vivo SPECT imaging of vesicular acetylcholine transporter using [(123)I]-IBVM in early Alzheimer's disease.
NeuroImage 2008;40(1):280-8.
2008: Satish K Chitneni; Lucette Garreau; Bernard J Cleynhens; Nele Evens; Marva Bex; Peter Vermaelen; Sylvie Chalon; Roger Busson; Denis Guilloteau; Koen Van Laere; Alfons Verbruggen; Guy Bormans
Improved synthesis and metabolic stability analysis of the dopamine transporter ligand [(18)F]FECT.
Nuclear medicine and biology 2008;35(1):75-82.
2007: Nicolas Giboureau; Patrick Emond; Roger R Fulton; David J Henderson; Sylvie Chalon; Lucette Garreau; Peter Roselt; Stefan Eberl; Sylvie Mavel; Sylvie Bodard; Michael J Fulham; Denis Guilloteau; Michael Kassiou
Ex vivo and in vivo evaluation of (2R,3R)-5-[(18)F]-fluoroethoxy- and fluoropropoxy-benzovesamicol, as PET radioligands for the vesicular acetylcholine transporter.
Synapse (New York, N.Y.) 2007;61(12):962-70.
2007: Patrick Emond; Sylvie Mavel; Yolanda Zea-Ponce; Michael Kassiou; Lucette Garreau; Sylvie Bodard; Marie-Laure Drossard; Sylvie Chalon; Denis Guilloteau
(E)-[125I]-5-AOIBV: a SPECT radioligand for the vesicular acetylcholine transporter.
Nuclear medicine and biology 2007;34(8):967-71.
2007: Françoise Baulieu; Michèle BOIRON; Philippe Bertrand; Denis Guilloteau; Jean-Louis Baulieu; Etienne-Henry Metman
Evaluation of a solid bolus suitable for esophageal scintigraphy.
Dysphagia 2007;22(4):281-9.
2007: Johnny Vercouillie; Winnie Deuther-Conrad; Matthias Scheunemann; Patrick Emond; Steffen Fischer; Uta Funke; Jörg Steinbach; Denis Guilloteau; Peter Brust
New fluoro-diphenylchalcogen derivatives to explore the serotonin transporter by PET.
Bioorganic & medicinal chemistry letters 2007;17(17):4991-5.
2007: Mitchell Quinlivan; Sylvie Chalon; Jackie Vergote; Jasmine Henderson; Andrew Katsifis; Michael Kassiou; Denis Guilloteau
Decreased vesicular acetylcholine transporter and alpha(4)beta(2) nicotinic receptor density in the rat brain following 192 IgG-saporin immunolesioning.
Neuroscience letters 2007;415(2):97-101.
2007: Wadad Saba; Héric Valette; Marie-Anne Schöllhorn-Peyronneau; Christine Coulon; Michèle Ottaviani; Sylvie Chalon; Frederic Dolle; Patrick Emond; Christer Halldin; Julie Helfenbein; Jean-Claude Madelmont; Jean-Bernard Deloye; Denis Guilloteau; Michel Bottlaender
[11C]LBT-999: a suitable radioligand for investigation of extra-striatal dopamine transporter with PET.
Synapse (New York, N.Y.) 2007;61(1):17-23.
2006: Thaer Assaad; Sylvie Mavel; Stanley M Parsons; Shane Kruse; Laurent Galineau; Hassan Allouchi; Michael Kassiou; Sylvie Chalon; Denis Guilloteau; Patrick Emond
Synthesis and in vitro evaluation of N-substituted aza-trozamicol analogs as vesicular acetylcholine transporter ligands.
Bioorganic & medicinal chemistry letters 2006;16(10):2654-7.
2006: Sylvie Chalon; Håkan Hall; Wadad Saba; Lucette Garreau; Frédéric Dollé; Christer Halldin; Patrick Emond; Michel Bottlaender; Jean-Bernard Deloye; Julie Helfenbein; Jean-Claude Madelmont; Sylvie Bodard; Zoïa Mincheva; Jean-Claude Besnard; Denis Guilloteau
Pharmacological characterization of (E)-N-(4-fluorobut-2-enyl)-2beta-carbomethoxy-3beta-(4'-tolyl)nortropane (LBT-999) as a highly promising fluorinated ligand for the dopamine transporter.
The Journal of pharmacology and experimental therapeutics 2006;317(1):147-52.
2006: Johnny Vercouillie; Sylvie Mavel; Laurent Galineau; Tiziana Ragusa; Robert Innis; Michael Kassiou; Sylvie Chalon; Frédéric Dollé; Jean-Claude Besnard; Denis Guilloteau; Patrick Emond
Synthesis and in vitro evaluation of novel derivatives of diphenylsulfide as serotonin transporter ligands.
Bioorganic & medicinal chemistry letters 2006;16(5):1297-300.
2006: Sylvie Mavel; Branko Dikic; Somchit Palakas; Patrick Emond; Ivan Greguric; Adrienne Gomez de Gracia; Filomena Mattner; Manuel Garrigos; Denis Guilloteau; Andrew Katsifis
Synthesis and biological evaluation of a series of flavone derivatives as potential radioligands for imaging the multidrug resistance-associated protein 1 (ABCC1/MRP1).
Bioorganic & medicinal chemistry 2006;14(5):1599-607.
2006: Frédéric Dollé; Patrick Emond; Sylvie Mavel; Stéphane Demphel; Françoise Hinnen; Zoïa Mincheva; Wadad Saba; Héric Valette; Sylvie Chalon; Christer Halldin; Julie Helfenbein; Joël Legaillard; Jean-Claude Madelmont; Jean-Bernard Deloye; Michel Bottlaender; Denis Guilloteau
Synthesis, radiosynthesis and in vivo preliminary evaluation of [11C]LBT-999, a selective radioligand for the visualisation of the dopamine transporter with PET.
Bioorganic & medicinal chemistry 2006;14(4):1115-25.
2006: Julie Magnant; Laurent Vecellio; Michèle De Monte; Daniel Grimbert; Chantal Valat; Eric Boissinot; Denis Guilloteau; Etienne Lemarié; Patrice Diot
Comparative analysis of different scintigraphic approaches to assess pulmonary ventilation.
Journal of aerosol medicine : the official journal of the International Society for Aerosols in Medicine 2006;19(2):148-59.
2005: Christer Halldin; Johan Lundberg; Judit Sóvágó; Balázs Gulyás; Denis Guilloteau; Johnny Vercouillie; Patrick Emond; Sylvie Chalon; Jari Tarkiainen; Jukka Hiltunen; Lars Farde
[(11)C]MADAM, a new serotonin transporter radioligand characterized in the monkey brain by PET.
Synapse (New York, N.Y.) 2005;58(3):173-83.
2005: Laurent Galineau; Catherine Belzung; Ercem Kodas; Sylvie Bodard; Denis Guilloteau; Sylvie Chalon
Prenatal 3,4-methylenedioxymethamphetamine (ecstasy) exposure induces long-term alterations in the dopaminergic and serotonergic functions in the rat.
Brain research. Developmental brain research 2005;154(2):165-76.
2005: Yolanda Zea-Ponce; Sylvie Mavel; Thaer Assaad; Shane E Kruse; Stanley M Parsons; Patrick Emond; Sylvie Chalon; Nicolas Giboureau; Michael Kassiou; Denis Guilloteau
Synthesis and in vitro evaluation of new benzovesamicol analogues as potential imaging probes for the vesicular acetylcholine transporter.
Bioorganic & medicinal chemistry 2005;13(3):745-53.
2005: Denis Guilloteau; Sylvie Chalon
PET and SPECT exploration of central monoaminergic transporters for the development of new drugs and treatments in brain disorders.
Current pharmaceutical design 2005;11(25):3237-45.
2004: Laurent Galineau; Ercem Kodas; Denis Guilloteau; Marie-Paule Vilar; Sylvie Chalon
Ontogeny of the dopamine and serotonin transporters in the rat brain: an autoradiographic study.
Neuroscience letters 2004;363(3):266-71.
2004: Ercem Kodas; Laurent Galineau; Sylvie Bodard; Sylvie Vancassel; Denis Guilloteau; Jean-Claude Besnard; Sylvie Chalon
Serotoninergic neurotransmission is affected by n-3 polyunsaturated fatty acids in the rat.
Journal of neurochemistry 2004;89(3):695-702.
2004: Sylvie Chalon; Cécile Bronquard; Johnny Vercouillie; Ercem Kodas; Lucette Garreau; Sylvie Bodard; Patrick Emond; Jean-Claude Besnard; Denis Guilloteau
ADAM is an effective tool for in vivo study of serotonergic function: validation in rat models.
Synapse (New York, N.Y.) 2004;52(2):136-42.
2003: Wassilios Meissner; Caroline Prunier; Denis Guilloteau; Sylvie Chalon; Christian E Gross; Erwan Bezard
Time-course of nigrostriatal degeneration in a progressive MPTP-lesioned macaque model of Parkinson's disease.
Molecular neurobiology 2003;28(3):209-18.
2003: Mitchell Quinlivan; Filomena Mattner; Vahan Papazian; Jia Zhou; Andrew Katsifis; Patrick Emond; Sylvie Chalon; Alan P Kozikowski; Denis Guilloteau; Michael Kassiou
Synthesis and evaluation of iodine-123 labelled tricyclic tropanes as radioligands for the serotonin transporter.
Nuclear medicine and biology 2003;30(7):741-6.
2003: Christer Halldin; Nina Erixon-Lindroth; Stefan Pauli; Yuan-Hwa Chou; Yoshiro Okubo; Per Karlsson; Camilla Lundkvist; Hans Olsson; Denis Guilloteau; Patrick Emond; Lars Farde
[(11)C]PE2I: a highly selective radioligand for PET examination of the dopamine transporter in monkey and human brain.
European journal of nuclear medicine and molecular imaging 2003;30(9):1220-30.
2003: Sylvain Cantagrel; Catherine Krier; Sarah Ducrocq; Sylvie Bodard; Valérie Payen; Jean Laugier; Denis Guilloteau; Sylvie Chalon
Hypoxic preconditioning reduces apoptosis in a rat model of immature brain hypoxia-ischaemia.
Neuroscience letters 2003;347(2):106-10.
2003: Caroline Prunier; Erwan Bézard; Jérôme Montharu; Marina Mantzarides; Jean-Claude Besnard; Jean-Louis Baulieu; Christian Gross; Denis Guilloteau; Sylvie Chalon
Presymptomatic diagnosis of experimental Parkinsonism with 123I-PE2I SPECT.
NeuroImage 2003;19(3):810-6.
2003: Caroline Bagot-Guéret; Marie-Delphine Le Bas; Sylvie Tymciu; Mircea Darabantu; Patrick Emond; Denis Guilloteau; Marie-Claire Lasne; Anne Wijkhuisen; Louisa Barré; Cécile Perrio
Synthesis and biological evaluation of halogenated naphthyridone carboxamides as potential ligands for in vivo imaging studies of substance P receptors.
Bioconjugate chemistry 2003;14(3):629-41.
2003: Caroline Prunier; Pierre Payoux; Denis Guilloteau; Sylvie Chalon; Bruno Giraudeau; Cynthia Majorel; Mathieu Tafani; Erwan Bezard; Jean Paul Esquerré; Jean-Louis Baulieu
Quantification of dopamine transporter by 123I-PE2I SPECT and the noninvasive Logan graphical method in Parkinson's disease.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2003;44(5):663-70.
2003: Sylvie Chalon; Jari Tarkiainen; Lucette Garreau; Håkan Hall; Patrick Emond; Johnny Vercouillie; Lars Farde; Philippe Dasse; Katarina Varnas; Jean-Claude Besnard; Christer Halldin; Denis Guilloteau
Pharmacological characterization of N,N-dimethyl-2-(2-amino-4-methylphenyl thio)benzylamine as a ligand of the serotonin transporter with high affinity and selectivity.
The Journal of pharmacology and experimental therapeutics 2003;304(1):81-7.
2002: Johan Sandell; Meixiang Yu; Patrick Emond; Lucette Garreau; Sylvie Chalon; Kjell Någren; Denis Guilloteau; Christer Halldin
Synthesis, radiolabeling and preliminary biological evaluation of radiolabeled 5-methyl-6-nitroquipazine, a potential radioligand for the serotonin transporter.
Bioorganic & medicinal chemistry letters 2002;12(24):3611-3.
2002: Johan Sandell; Christer Halldin; Judith Sovago; Yuan-Hwa Chou; Balázs Gulyás; Meixiang Yu; Patrick Emond; Kjell Någren; Denis Guilloteau; Lars Farde
PET examination of [(11)C]5-methyl-6-nitroquipazine, a radioligand for visualization of the serotonin transporter.
Nuclear medicine and biology 2002;29(6):651-6.
2002: Ercem Kodas; Sylvie Vancassel; Bernard Lejeune; Denis Guilloteau; Sylvie Chalon
Reversibility of n-3 fatty acid deficiency-induced changes in dopaminergic neurotransmission in rats: critical role of developmental stage.
Journal of lipid research 2002;43(8):1209-19.
2002: Christelle Gouhier; Sylvie Chalon; Anne Aubert-Pouessel; Marie-Claire Venier-Julienne; Christophe Jollivet; Jean-Pierre Benoit; Denis Guilloteau
Protection of dopaminergic nigrostriatal afferents by GDNF delivered by microspheres in a rodent model of Parkinson's disease.
Synapse (New York, N.Y.) 2002;44(3):124-31.
2002: Luc Zimmer; Sylvie Vancassel; Sylvain Cantagrel; Patrick Breton; Séraphin Delamanche; Denis Guilloteau; Georges Durand; Sylvie Chalon
The dopamine mesocorticolimbic pathway is affected by deficiency in n-3 polyunsaturated fatty acids.
The American journal of clinical nutrition 2002;75(4):662-7.
2002: Ercem Kodas; Guylène Page; Luc Zimmer; Sylvie Vancassel; Denis Guilloteau; Georges Durand; Sylvie Chalon
Neither the density nor function of striatal dopamine transporters were influenced by chronic n-3 polyunsaturated fatty acid deficiency in rodents.
Neuroscience letters 2002;321(1-2):95-9.
2002: Patrick Emond; Johnny Vercouillie; Robert B Innis; Sylvie Chalon; Sylvie Mavel; Yves Frangin; Christer Halldin; Jean-Claude Besnard; Denis Guilloteau
Substituted diphenyl sulfides as selective serotonin transporter ligands: synthesis and in vitro evaluation.
Journal of medicinal chemistry 2002;45(6):1253-8.
2002: Stéphanie Barc; Guylène Page; Laurence Barrier; Lucette Garreau; Denis Guilloteau; Bernard Fauconneau; Sylvie Chalon
Relevance of different striatal markers in assessment of the MPP+-induced dopaminergic nigrostriatal injury in rat.
Journal of neurochemistry 2002;80(3):365-74.
2001: Caroline Prunier; François Tranquart; Jean Philippe Cottier; B Giraudeau; Sylvie Chalon; Denis Guilloteau; B De Toffol; F Chossat; Alain Autret; Jean-Claude Besnard; Jean-Louis Baulieu
Quantitative analysis of striatal dopamine D2 receptors with 123 I-iodolisuride SPECT in degenerative extrapyramidal diseases.
Nuclear medicine communications 2001;22(11):1207-14.
2001: Sylvie Chalon; Sylvie Vancassel; Luc Zimmer; Denis Guilloteau; Georges Durand
Polyunsaturated fatty acids and cerebral function: focus on monoaminergic neurotransmission.
Lipids 2001;36(9):937-44.
2001: Erwan Bezard; Sandra Dovero; Caroline Prunier; Paula Ravenscroft; Sylvie Chalon; Denis Guilloteau; Alan R Crossman; Bernard Bioulac; Jonathan M Brotchie; Christian E Gross
Relationship between the appearance of symptoms and the level of nigrostriatal degeneration in a progressive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease.
The Journal of neuroscience : the official journal of the Society for Neuroscience 2001;21(17):6853-61.
2001: Sylvie Vancassel; Georges Durand; C Barthélémy; Bernard Lejeune; Joëlle Martineau; Denis Guilloteau; C Andrès; Sylvie Chalon
Plasma fatty acid levels in autistic children.
Prostaglandins, leukotrienes, and essential fatty acids 2001;65(1):1-7.
2001: Sylvain Cantagrel; Pierre Gressens; Sylvie Bodard; AL Suc; Jean Laugier; Denis Guilloteau; Sylvie Chalon
mRNA D(2) dopaminergic receptor expression after hypoxia-ischemia in rat immature brain.
Biology of the neonate 2001;80(1):68-73.
2001: Patrick Emond; Julie Helfenbein; Sylvie Chalon; Lucette Garreau; Johnny Vercouillie; Yves Frangin; Jean-Claude Besnard; Denis Guilloteau
Synthesis of tropane and nortropane analogues with phenyl substitutions as serotonin transporter ligands.
Bioorganic & medicinal chemistry 2001;9(7):1849-55.
2001: Patrice Diot; E Galinier; Daniel Grimbert; S Bugeon; Chantal Valat; Etienne Lemarié; Elisabeth Diot; Jean-Louis Baulieu; Jean-Claude Besnard; Denis Guilloteau
Characterization of 99mTc-DTPA aerosols for lung permeability studies.
Respiration; international review of thoracic diseases 2001;68(3):313-7.
2001: Erwan Bezard; Thomas Boraud; Sylvie Chalon; Jonathan M Brotchie; Denis Guilloteau; Christian E Gross
Pallidal border cells: an anatomical and electrophysiological study in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkey.
Neuroscience 2001;103(1):117-23.
2001: François Tranquart; Elie Saliba; L Barantin; M Lanneau; L Simmer; Denis Guilloteau; Jean-Louis Baulieu
D2 receptor imaging in neonates using I-123 iodobenzamide brain SPECT.
Clinical nuclear medicine 2001;26(1):36-40.
2000: Luc Zimmer; Ercem Kodas; Denis Guilloteau; Lucette Garreau; Jean-Claude Besnard; Sylvie Chalon
Microdialysis as a tool for in vivo study of dopamine transporter function in rat brains.
Journal of neuroscience methods 2000;103(2):137-44.
2000: Jean-Louis Baulieu; I Resche; M Bardies; A F Chauvet; J Lecloirec; J Malhaire; E Thomas; P Faurous; G Sassolas; Léandre Pourcelot; Jean-François Chatal; Denis Guilloteau; Jean-Claude Besnard
[131I]-TYR3-octreotide: clinical dosimetry and use for internal radiotherapy of metastatic paraganglioma and carcinoid tumors.
Nuclear medicine and biology 2000;27(8):809-813.
2000: C Gouhier; Sylvie Chalon; Marie-Claire Venier-Julienne; Sylvie Bodard; J Benoit; Jean-Claude Besnard; Denis Guilloteau
Neuroprotection of nerve growth factor-loaded microspheres on the D2 dopaminergic receptor positive-striatal neurones in quinolinic acid-lesioned rats: a quantitative autoradiographic assessment with iodobenzamide.
Neuroscience letters 2000;288(1):71-5.
2000: L Zimmer; S Delpal; Denis Guilloteau; J Aïoun; G Durand; S Chalon
Chronic n-3 polyunsaturated fatty acid deficiency alters dopamine vesicle density in the rat frontal cortex.
Neuroscience letters 2000;284(1-2):25-8.
2000: Luc Zimmer; S Delion-Vancassel; Georges Durand; Denis Guilloteau; Sylvie Bodard; Jean-Claude Besnard; Sylvie Chalon
Modification of dopamine neurotransmission in the nucleus accumbens of rats deficient in n-3 polyunsaturated fatty acids.
Journal of lipid research 2000;41(1):32-40.
1999: François Tranquart; Elie Saliba; L Zimmer; L Barantin; M Lanneau; Denis Guilloteau; Jean-Louis Baulieu
Dopamine D2 receptor brain imaging in the neonatal period using 123I-IBZM SPECT.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 1999;40(12):2126-7.
1999: Sylvie Chalon; Lucette Garreau; Patrick Emond; Luc Zimmer; M P Vilar; Jean-Claude Besnard; Denis Guilloteau
Pharmacological characterization of (E)-N-(3-iodoprop-2-enyl)-2beta-carbomethoxy-3beta-(4'-methylphenyl)n ortropane as a selective and potent inhibitor of the neuronal dopamine transporter.
The Journal of pharmacology and experimental therapeutics 1999;291(2):648-54.
1999: C Collet; P Lecomte; Denis Guilloteau; B Lejeune; C Lecomte; Jean-Claude Besnard
Luteinizing hormone measurement in polycystic ovary syndrome: a practical approach.
European journal of endocrinology / European Federation of Endocrine Societies 1999;141(3):225-30.
1999: Julie Helfenbein; Johan Sandell; Christer Halldin; Sylvie Chalon; Patrick Emond; Y Okubo; Yuan-Hwa Chou; Yves Frangin; L Douziech; L Gareau; Carl-Gunnar Swahn; Jean-Claude Besnard; Lars Farde; Denis Guilloteau
PET examination of three potent cocaine derivatives as specific radioligands for the serotonin transporter.
Nuclear medicine and biology 1999;26(5):491-9.
1999: Sylvie Chalon; Patrick Emond; Sylvie Bodard; M P Vilar; C Thiercelin; Jean-Claude Besnard; Denis Guilloteau
Time course of changes in striatal dopamine transporters and D2 receptors with specific iodinated markers in a rat model of Parkinson's disease.
Synapse (New York, N.Y.) 1999;31(2):134-9.
1999: Julie Helfenbein; Christian Loc'h; Michel Bottlaender; Patrick Emond; Christine Coulon; Michèle Ottaviani; Chantal Fuseau; Sylvie Chalon; Ilonka Guenther; Jean-Claude Besnard; Yves Frangin; Denis Guilloteau; Bernard Maziere
A selective radiobrominated cocaine analogue for imaging of dopamine uptake sites: pharmacological evaluation and PET experiments.
Life sciences 1999;65(25):2715-26.
1999: L Zimmer; G Durand; Denis Guilloteau; S Chalon
n-3 polyunsaturated fatty acid deficiency and dopamine metabolism in the rat frontal cortex.
Lipids 1999;34 Suppl():S251.
1999: Jean-Louis Baulieu; M J Ribeiro; C Levilion-Prunier; François Tranquart; J R Chartier; Denis Guilloteau; Jean Philippe Cottier; Jean-Claude Besnard; Léandre Pourcelot; Alain Autret
Effects of the method of drawing regions of interest on the differential diagnosis of extrapyramidal syndromes using 123I-iodolisuride SPET.
Nuclear medicine communications 1999;20(1):77-84.
1999: Håkan Hall; Christer Halldin; Denis Guilloteau; S Chalon; Patrick Emond; Jean-Claude Besnard; Lars Farde; G Sedvall
Visualization of the dopamine transporter in the human brain postmortem with the new selective ligand [125I]PE2I.
NeuroImage 1999;9(1):108-16.
1998: Sylvie Chalon; S Delion-Vancassel; Catherine Belzung; Denis Guilloteau; A M Leguisquet; Jean-Claude Besnard; Georges Durand
Dietary fish oil affects monoaminergic neurotransmission and behavior in rats.
The Journal of nutrition 1998;128(12):2512-9.
1998: Patrick Emond; Lars Farde; Sylvie Chalon; Catherine Belzung; V Mauclaire; J P Chiron; Christer Halldin; Jean-Claude Besnard; Denis Guilloteau
Toxicity, mutagenicity, and behavioral effects of beta-CIT, a ligand for dopamine transporter exploration by SPECT.
Nuclear medicine and biology 1998;25(4):405-9.
1998: Denis Guilloteau; Patrick Emond; Jean-Louis Baulieu; Lucette Garreau; Yves Frangin; Léandre Pourcelot; L Mauclaire; Jean-Claude Besnard; Sylvie Chalon
Exploration of the dopamine transporter: in vitro and in vivo characterization of a high-affinity and high-specificity iodinated tropane derivative (E)-N-(3-iodoprop-2-enyl)-2beta-carbomethoxy-3beta-(4'-m ethylph enyl)nortropane (PE2I).
Nuclear medicine and biology 1998;25(4):331-7.
1998: Jyrki T Kuikka; Jean-Louis Baulieu; Jukka Hiltunen; Christer Halldin; Kim A Bergström; Lars Farde; Patrick Emond; Sylvie Chalon; M Yu; T Nikula; T Laitinen; Jari Karhu; Erkki Tupala; Tero Hallikainen; V Kolehmainen; L Mauclaire; Bernard Maziere; Jari Tiihonen; Denis Guilloteau
Pharmacokinetics and dosimetry of iodine-123 labelled PE2I in humans, a radioligand for dopamine transporter imaging.
European journal of nuclear medicine 1998;25(5):531-4.
1998: Luc Zimmer; S Hembert; Georges Durand; Patrick Breton; Denis Guilloteau; Jean-Claude Besnard; Sylvie Chalon
Chronic n-3 polyunsaturated fatty acid diet-deficiency acts on dopamine metabolism in the rat frontal cortex: a microdialysis study.
Neuroscience letters 1998;240(3):177-81.
1998: François Huguet; A Guerraoui; Laurence Barrier; Denis Guilloteau; Claude Tallineau; Sylvie Chalon
Changes in excitatory amino acid levels and tissue energy metabolites of neonate rat brain after hypoxia and hypoxia-ischemia.
Neuroscience letters 1998;240(2):102-6.
1997: Lucette Garreau; Patrick Emond; Catherine Belzung; Denis Guilloteau; Yves Frangin; Jean-Claude Besnard; Sylvie Chalon
N-(3-lodoprop-2E-enyl)-2beta-carbomethoxy-3beta-(3',4'-dichloro phenyl)nortropane (beta-CDIT), a tropane derivative: pharmacological characterization as a specific ligand for the dopamine transporter in the rodent brain.
The Journal of pharmacology and experimental therapeutics 1997;282(1):467-74.
1997: Patrick Emond; Sylvie Chalon; Lucette Garreau; A M Dognon; Sylvie Bodard; Yves Frangin; Jean-Louis Baulieu; Jean-Claude Besnard; Denis Guilloteau
A new iodinated tropane derivative (beta-CDIT) for in vivo dopamine transporter exploration: comparison with beta-CIT.
Synapse (New York, N.Y.) 1997;26(1):72-80.
1997: Patrick Emond; Lucette Garreau; Sylvie Chalon; M Boazi; M Caillet; J Bricard; Yves Frangin; L Mauclaire; Jean-Claude Besnard; Denis Guilloteau
Synthesis and ligand binding of nortropane derivatives: N-substituted 2beta-carbomethoxy-3beta-(4'-iodophenyl)nortropane and N-(3-iodoprop-(2E)-enyl)-2beta-carbomethoxy-3beta-(3',4'-disubstituted phenyl)nortropane. New high-affinity and selective compounds for the dopamine transporter.
Journal of medicinal chemistry 1997;40(9):1366-72.
1997: S Delion; Sylvie Chalon; Denis Guilloteau; B Lejeune; Jean-Claude Besnard; Georges Durand
Age-related changes in phospholipid fatty acid composition and monoaminergic neurotransmission in the hippocampus of rats fed a balanced or an n-3 polyunsaturated fatty acid-deficient diet.
Journal of lipid research 1997;38(4):680-9.
1997: A Zouakia; Denis Guilloteau; Luc Zimmer; Jean-Claude Besnard; S Chalon
Evolution of dopamine receptors in the rat after neonatal hypoxia-ischemia: autoradiographic studies.
Life sciences 1997;60(2):151-62.
1996: Sylvie Chalon; christian pellevoisin; Sylvie Bodard; M P Vilar; Jean-Claude Besnard; Denis Guilloteau
Iodinated PK 11195 as an ex vivo marker of neuronal injury in the lesioned rat brain.
Synapse (New York, N.Y.) 1996;24(4):334-9.
1996: christian pellevoisin; Denis Guilloteau; Jean-Louis Baulieu; Christian Loc'h; A M Dognon; L Mauclaire; J C Saccavini; Jean-Claude Besnard; Sylvie Chalon
Iodolisuride and iodobenzamide, two ligands for SPECT exploration of the dopaminergic D2 receptors: a comparative study.
Synapse (New York, N.Y.) 1996;24(1):79-86.
1996: F Huguet; D Fagret; M Caillet; A Piriou; Jean-Claude Besnard; Denis Guilloteau
Interaction of metaiodobenzylguanidine with cardioactive drugs: an in vitro study.
European journal of nuclear medicine 1996;23(5):546-9.
1996: S Delion; Sylvie Chalon; Denis Guilloteau; Jean-Claude Besnard; Georges Durand
alpha-Linolenic acid dietary deficiency alters age-related changes of dopaminergic and serotoninergic neurotransmission in the rat frontal cortex.
Journal of neurochemistry 1996;66(4):1582-91.
1996: christian pellevoisin; Sylvie Chalon; H F Kung; Jean-Claude Besnard; Denis Guilloteau
Is TISCH a suitable tracer for in vivo study of modifications of the dopamine D-1 receptor?
Nuclear medicine and biology 1996;23(1):75-8.
1996: H Rafii; Sylvie Chalon; J E Ombetta; Yves Frangin; L Pourcelot; Jean-Claude Besnard; Sylvie Bodard; Denis Guilloteau
An iodinated derivative of moclobemide as potential radioligand for brain MAO-A exploration.
Life sciences 1996;58(14):1159-69.
1995: I Lena; J E Ombetta; Sylvie Chalon; A M Dognon; Jean-Louis Baulieu; Yves Frangin; Lucette Garreau; Jean-Claude Besnard; Denis Guilloteau
Iododerivative of pargyline: a potential tracer for the exploration of monoamine oxidase sites by SPECT.
Nuclear medicine and biology 1995;22(6):727-36.
1995: C Branger; Lucette Garreau; A M Dognon; Yves Frangin; M Caillet; J E Ombetta-Goka; Sylvie Chalon; Jean-Claude Besnard; Denis Guilloteau
Synthesis of 4'-iodo-5-methoxy-valerophenone O-(2-aminoethyl)oxime as an agent for exploration of serotoninergic transporter.
Nuclear medicine and biology 1995;22(2):157-64.
1994: S Delion; Sylvie Chalon; J Hérault; Denis Guilloteau; Jean-Claude Besnard; Georges Durand
Chronic dietary alpha-linolenic acid deficiency alters dopaminergic and serotoninergic neurotransmission in rats.
The Journal of nutrition 1994;124(12):2466-76.
1994: François Tranquart; F H Le Bras; Bertrand de Toffol; Alain Autret; Denis Guilloteau; Jean-Louis Baulieu
[Progressive supranuclear paralysis. Quantification of dopamine D2 receptors using radionuclide tomography].
Presse médicale (Paris, France : 1983) 1994;23(28):1299-300.
1994: A Zouakia; Sylvie Chalon; H F Kung; A M Dognon; E Saliba; Jean-Claude Besnard; Denis Guilloteau
Radioiodinated tracers for the evaluation of dopamine receptors in the neonatal rat brain after hypoxic-ischemic injury.
European journal of nuclear medicine 1994;21(6):488-92.
1993: christian pellevoisin; Sylvie Chalon; A Zouakia; A M Dognon; Yves Frangin; Jean-Louis Baulieu; Jean-Claude Besnard; Denis Guilloteau
Comparison of two radioiodinated ligands of dopamine D2 receptors in animal models: iodobenzamide and iodoethylspiperone.
Life sciences 1993;52(23):1851-60.
1992: C Foulon; Lucette Garreau; Sylvie Chalon; G Desplanches; Yves Frangin; Jean-Claude Besnard; Jean-Louis Baulieu; Denis Guilloteau
Synthesis and in vitro binding properties of halogenated analogues of GBR as new dopamine uptake carrier ligands.
International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology 1992;19(5):597-600.
1992: M J Ribeiro-Barras; C Foulon; Jean-Louis Baulieu; Denis Guilloteau; PHILIPPE BOUGNOUX; J Lansac; Jean-Claude Besnard
Estrogen receptor imaging with 17 alpha-[123I]iodovinyl-11 beta-methoxyestradiol (MIVE2)--Part II. Preliminary results in patients with breast carcinoma.
International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology 1992;19(3):263-7.
1992: C Foulon; Denis Guilloteau; Jean-Louis Baulieu; M J Ribeiro-Barras; G Desplanches; Yves Frangin; Jean-Claude Besnard
Estrogen receptor imaging with 17 alpha-[123I]iodovinyl-11 beta-methoxyestradiol (MIVE2)--Part I. Radiotracer preparation and characterization.
International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology 1992;19(3):257-61.
1990: Denis Guilloteau; R Perdrisot; C Calmettes; Jean-Louis Baulieu; P Lecomte; G Kaphan; G Milhaud; J C Besnard; Pierre Jallet; Jean-Claude Bigorgne
Diagnosis of medullary carcinoma of the thyroid (MCT) by calcitonin assay using monoclonal antibodies: criteria for the pentagastrin stimulation test in hereditary MCT.
The Journal of clinical endocrinology and metabolism 1990;71(4):1064-7.
1990: R Perdrisot; Jean-Claude Bigorgne; Denis Guilloteau; Pierre Jallet
Monoclonal immunoradiometric assay of calcitonin improves investigation of familial medullary thyroid carcinoma.
Clinical chemistry 1990;36(2):381-3.
1990: Sylvie Chalon; C Guimbal; Denis Guilloteau; W Mayo; François Huguet; M H Schmitt; G Desplanches; Jean-Louis Baulieu; Jean-Claude Besnard
Iodobenzamide for in vivo exploration of central dopamine receptors: evaluation in animal models of supersensitivity.
Life sciences 1990;47(8):729-34.
1990: Jean-Louis Baulieu; François Huguet; Sylvie Chalon; P Gerard; Yves Frangin; Jean-Claude Besnard; L Pourcelot; Denis Guilloteau
[125I]MIBG uptake and release in different regions of the rat brain.
International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology 1990;17(5):511-4.
1990: Sylvie Chalon; Yves Frangin; Denis Guilloteau; M Caillet; C Guimbal; M H Schmitt; G Desplanches; Jean-Louis Baulieu; Jean-Claude Besnard
Iodoethylspiperone, a new potential agent for exploration of central dopamine D2 receptors: synthesis and preliminary in vivo study.
International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology 1990;17(4):389-95.
1989: Jean-Claude Bigorgne; R Perdrisot; Denis Guilloteau; V Beldent; Vincent Rohmer; Pierre Jallet
[Detection of medullary cancer of the thyroid. Contribution of calcitonin determination by an immunoradiometric method using 2 monoclonal antibodies].
Presse médicale (Paris, France : 1983) 1989;18(35):1754.
1988: Jean-Louis Baulieu; Denis Guilloteau; F Baulieu; O Le Floch; C Chambon; L Pourcelot; Jean-Claude Besnard
Therapeutic effectiveness of iodine-131 MIBG metastases of a nonsecreting paraganglioma.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 1988;29(12):2008-13.
1988: Denis Guilloteau; François Huguet; Sylvie Chalon; Jean-Louis Baulieu; P Gerard; G Narcisse; L Pourcelot; Jean-Claude Besnard
MIBG and catecholamine storage in the brain: an in-vitro study.
International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology 1988;15(6):723-4.
1988: Denis Guilloteau; Sylvie Chalon; Jean-Louis Baulieu; François Huguet; G Desplanches; C Chambon; M P Vilar; L Pourcelot; Jean-Claude Besnard
Comparison of MIBG and monoamines uptake mechanisms: pharmacological animal and blood platelets studies.
European journal of nuclear medicine 1988;14(7-8):341-4.
1987: Jean-Louis Baulieu; Denis Guilloteau; M J Delisle; R Perdrisot; P Gardet; N Delépine; F Baulieu; J L Dupont; Jean-Noël Talbot; G Coutris
Radioiodinated meta-iodobenzylguanidine uptake in medullary thyroid cancer. A French cooperative study.
Cancer 1987;60(9):2189-94.
1984: Jean-Louis Baulieu; Denis Guilloteau; F Fetissof; J Caron; P Lecomte; Jean-Louis Guilmot; F Lipinski; F Baulieu; Roland Itti; L Pourcelot
[Sympathetic paraganglioma. Scintigraphic detection using a new labeled molecule, meta-iodobenzylguanidine].
Presse médicale (Paris, France : 1983) 1984;13(27):1679-82.
1984: Denis Guilloteau; Jean-Louis Baulieu; François Huguet; C Viel; C Chambon; Chantal Valat; F Baulieu; Roland Itti; L Pourcelot; G Narcisse
Meta-iodobenzylguanidine adrenal medulla localization: autoradiographic and pharmacologic studies.
European journal of nuclear medicine 1984;9(6):278-81.